jackley

UBS SEES GLP-1 DRUGS WEIGHING ON RESTAURANTS UBS says growing use of GLP-1 weight-loss drugs could become a headwind for restaurant sales as users cut calories, dine out less, and shift toward healthier foods. The bank expects restaurants to increasingly adapt menus with smaller portions and healthier options, with fast food and less healthy chains most at risk.

Name a fat guy with aura:

Reminder that the average RW anime enjoyer on here can smoke this hebress in the field she paid to study.

There's something so timeless and iconic about the design of Control Panel in System 1 But of course it doesn't scale well when having to add text + new elements as we see in System 3... hence the split design from System 5 And then there's the multi window madness of System 7

Retatrutide phase 3 obesity trial results are out, and it's safe to say that this is the next generation of obesity medicine: - 28.3% bodyweight lost on 12mg over 80 weeks (70.3 lbs) - 30.3% at 104 weeks in higher-BMI patients (85 lbs) - 45.3% of patients hit 30%+ weight loss - 65.3% dropped below the obesity BMI threshold - notable drops in blood pressure, triglycerides, cholesterol & inflammation - no cardiac or liver signals For those of you who are new to peptides, the reason retatrutide works better than semaglutide and tirzepatide is its mechanism. Semaglutide hits one hormone, tirzepatide hits two, but retatrutide hits three: GLP-1, GIP, and glucagon. Glucagon increases the amount of energy your body burns at rest so you eat less and burn more at the same time. Retatrutide is the drug that has the potential to end the obesity pandemic.

Photoshop logo evolution 1988–2025